PALO ALTO, Calif., July 23 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings of $74 million ($0.58 per diluted share) for the third quarter of fiscal year 2008 versus net earnings in the year-ago quarter of $50 million ($0.39 per diluted share). Compared to the same period last fiscal year, third quarter revenues grew 21 percent to $513 million, net orders rose 15 percent to $575 million, and the quarter- ending backlog increased 13 percent to $1.8 billion.
"This was an excellent quarter for our company," said Tim Guertin, president and CEO of Varian Medical Systems. "Our Oncology Systems, X-Ray Products, and Security businesses contributed to significant growth in revenues. High shipment volumes, product mix, and faster than expected Oncology product acceptances contributed to the revenue growth, a nearly 1- point improvement in the gross margin, and 35 percent growth in operating earnings versus the year-ago quarter. Higher operating earnings together with an unusually low 18 percent tax rate stemming from discrete tax benefits led to a 49 percent increase in net earnings per diluted share versus the year ago period."
The company generated $114 million in cash flow from operations in the quarter and ended the period with $406 million in cash and cash equivalents and $107 million of debt. Compared to the year-ago quarter, days sales outstanding improved by 14 days to 79. During the quarter, the company spent $62 million to repurchase 1.2 million shares of common stock under a 12 million share repurchase authorization that extends through the end of this calendar year.
The Oncology Systems business, including radiotherapy, radiosurgery, and brachytherapy products, reported third quarter revenues of $408 million, up 21 percent from the year-ago period. This business recorded third quarter net orders of $461 million, up 12 percent from the same period last year with 12 percent growth in North America and 13 percent growth in international markets.
"We continued to experience tremendous demand for our RapidArc™ products for faster, more precise image guided IMRT during the quarter," Guertin said. "Once again, even after very strong initial demand for RapidArc, we booked about 70 orders for this capability on new high energy machines during the quarter. Clinical use has commenced at several sites." Higher unit volumes for treatment machines and accessories for image-guided radiotherapy as well as service also drove Oncology Systems' net order growth during the quarter.
Revenues for the X-Ray Products business, including X-ray tubes and flat panel detectors for filmless imaging, were $77 million for the third quarter, up 22 percent from the year-ago quarter. Net orders for the quarter were $85 million, up 45 percent from the same period last year driven by continued strong demand for flat panel detectors.
"Our flat panel business grew strongly with the help of a more than $11 million order from a large new customer with a next-generation digital imaging system for medical diagnostics," Guertin said. "On top of adding important new customers, many of our existing customers have increased their order volumes."
The company's Other category, comprised of the Security and Inspection Products business, the ACCEL proton therapy business, and the Ginzton Technology Center, reported combined third quarter revenues of $28 million, up 23 percent from the same period last fiscal year due to growth in the security business.
Net orders for the Other category were $29 million, down 2 percent from the year-ago period when the company acquired Bio-Imaging Research (BIR), a supplier of detectors and software for processing and analyzing X-ray images in security and inspection systems. Excluding $3 million in acquired backlog from BIR in the year-ago quarter, net orders for this category grew by 8 percent versus the year-ago quarter with a 12 percent increase in net orders for security products.
"Our security business continued to expand with orders for high energy X-ray screening systems for ports and borders in Europe, the U.S. and the Far East," said Guertin.
"For the full fiscal year 2008, we believe that total company revenues should increase by about 17 to 18 percent above the fiscal 2007 total," Guertin said. "Net earnings per diluted share for fiscal year 2008 should grow by about 22 percent over the total for fiscal year 2007. At this early stage, we estimate that revenues for fiscal 2009 could grow by about 12 percent and that earnings per diluted share should grow at a slightly faster rate than revenues."
Investor Conference Call
Varian Medical Systems is scheduled to conduct its third quarter fiscal year 2008 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at http://www.varian.com/ where it will be archived for a year. To access the call via telephone, dial 1-800-329-9097 from inside the U.S. or 1-617-614-4929 from outside the U.S. and enter confirmation code 70611804. The replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 79882121. The telephone replay will be available through 5 p.m. PT, Friday, July 25, 2008.
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 60 sales and support offices around the world. For more information, visit http://www.varian.com/.
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as RapidArc therapy, image-guided radiation therapy (IGRT), stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "estimate," "believe," "expect," "could," "can," "grow," "should" or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include demand for the company's products; the company's ability to develop and commercialize new products; the company's ability to meet demand for manufacturing capacity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the company's ability to maintain or increase operating margins; the impact of competitive products and pricing; the effect of economic conditions, currency exchange rates, and tax rates; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements for product clearances or to comply with Food and Drug Administration and other regulatory regulations or procedures; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the possibility that material product liability claims could harm future revenues or require the company to pay uninsured claims; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the impact of managed care initiatives, other health care reforms, and/or third-party reimbursement levels and credit availability for capital expenditures for cancer care; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the risk of operations interruptions due to terrorism, disease or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
A summary of earnings and other financial information follows. Varian Medical Systems, Inc. and Subsidiaries Consolidated Statements of Earnings (Unaudited) (Dollars and shares in millions, except per share amounts) Q3 QTR Q3 QTR Q3 YTD Q3 YTD 2008 2007 2008 2007 Net orders $574.8 498.9 1,586.8 1,435.1 Oncology Systems 461.4 410.9 1,260.2 1,113.7 X-Ray Products 84.5 58.4 242.6 193.4 Other 28.9 29.6 84.0 128.0 Order backlog $1,786.8 1,581.6 1,786.8 1,581.6 Revenues $512.8 423.7 1,498.9 1,254.2 Oncology Systems 407.7 337.7 1,189.2 1,012.6 X-Ray Products 77.2 63.3 222.1 191.2 Other 27.9 22.7 87.6 50.4 Cost of revenues (1) $302.3 253.2 886.4 738.4 Gross margin 210.5 170.5 612.5 515.8 As a percent of revenues 41.1% 40.2% 40. 9% 41.1% Operating expenses Research and development (1) 36.0 29.2 97.2 84.6 Selling, general and administrative (1) 85.2 75.2 238.6 208.6 Operating earnings 89.3 66.1 276.7 222.6 As a percent of revenues 17.4% 15.6% 18.5% 17.7% Interest income, net 1.2 1.6 4.3 6.1 Earnings before taxes 90.5 67.7 281.0 228.7 Taxes on earnings (1) 16.3 17.4 80.0 67.9 Net earnings(1) $74.2 50.3 201.0 160.8 Net earnings per share - basic:(1) $0.60 0.40 1.61 1.26 Net earnings per share - diluted:(1) $0.58 0.39 1.58 1.22 Shares used in the calculation of net earnings per share: Average shares outstanding - basic 124.6 127.0 124.9 128.1 Average shares outstanding - diluted 127.1 129.9 127.6 131.4 (1) Includes amounts for total share-based compensation expense and its related tax benefits. (in millions, except per share amounts) Q3 QTR Q3 QTR Q3 YTD Q3 YTD 2008 2007 2008 2007 Costs of revenues $2.1 2.0 5.6 6.0 Research & development 1.4 1.2 3.5 3.8 Selling, general & administrative 8.0 7.6 21.0 24.0 Total 11.5 10.8 30.1 33.8 Taxes on earnings - SFAS 123R (3.8) (3.7) (10.0) (11.5) Net earnings $7.7 7.1 20.1 22.3 Net earnings per diluted share - share-based compensation expense $0.06 0.05 0.16 0.17 Net earnings per diluted share - excluding share-based compensation expense $0.64 0.44 1.73 1.39 Varian Medical Systems, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands) June 27, September 28, 2008 2007 (1) (Unaudited) Assets Current assets Cash and cash equivalents $405,684 $263,246 Accounts receivable, net 442,650 507,040 Inventories 304,306 233,743 Deferred tax assets and other 202,538 156,200 Total current assets 1,355,178 1,160,229 Property, plant and equipment 442,835 386,531 Accumulated depreciation and amortization (233,813) (214,877) Property, plant and equipment, net 209,022 171,654 Goodwill 214,927 205,553 Other assets 161,857 146,939 Total assets $1,940,984 $1,684,375 Liabilities and Stockholders' Equity Current liabilities Accounts payable $103,791 $92,600 Accrued expenses 245,687 299,052 Deferred revenues 138,129 101,839 Product warranty 52,440 51,290 Advance payments from customers 214,311 186,936 Short-term borrowings 66,884 41,000 Current maturities of long-term debt 7,983 8,970 Total current liabilities 829,225 781,687 Other long-term liabilities 126,977 40,847 Long-term debt 32,460 40,386 Total liabilities 988,662 862,920 Stockholders' Equity Common stock 124,877 125,215 Capital in excess of par value 391,771 311,411 Retained earnings and accumulated other comprehensive loss 435,674 384,829 Total stockholders' equity 952,322 821,455 Total liabilities and stockholders' equity $1,940,984 $1,684,375 (1) The condensed consolidated balance sheet as of September 28, 2007 was derived from audited financial statements as of that date. FOR INFORMATION CONTACT: Elisha Finney (650) 424-6803 email@example.com Spencer Sias (650) 424-5782 firstname.lastname@example.org
SOURCE: Varian Medical Systems
Web site: http://www.varian.com/